These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 15991260

  • 1. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A, Ziolkowska-Kochan M, Rybakowski JK.
    Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
    [Abstract] [Full Text] [Related]

  • 2. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I.
    Dement Geriatr Cogn Disord; 2007 Aug; 23(5):301-6. PubMed ID: 17356273
    [Abstract] [Full Text] [Related]

  • 3. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E, Onor ML, Saina M, Maso E.
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [Abstract] [Full Text] [Related]

  • 4. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
    Wallin AK, Andreasen N, Eriksson S, Båtsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Rydén M, Wallin A, Jonsson M, Olofsson H, Londos E, Wattmo C, Eriksdotter Jonhagen M, Minthon L, Swedish Alzheimer Treatment Study Group.
    Dement Geriatr Cogn Disord; 2007 Nov; 23(3):150-60. PubMed ID: 17312368
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T, Retz-Junginger P, Retz W, Supprian T, Rösler M.
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
    Wattmo C, Hansson O, Wallin AK, Londos E, Minthon L.
    Dement Geriatr Cogn Disord; 2008 Apr; 26(3):203-11. PubMed ID: 18769065
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernández-Ferràndiz M, Morante-Muñoz V, Isern-Vila A, Gelada-Batlle E, Majó-Llopart J.
    Dement Geriatr Cogn Disord; 2005 Apr; 19(4):189-95. PubMed ID: 15677866
    [Abstract] [Full Text] [Related]

  • 13. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wiig EH, Annas P, Basun H, Andreasen N, Lannfelt L, Zetterberg H, Blennow K, Minthon L.
    Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
    [Abstract] [Full Text] [Related]

  • 14. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, Trequattrini A, Upgrade Study Group.
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
    Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS.
    Int J Clin Pract; 2002 Nov; 56(6):441-6. PubMed ID: 12166542
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [Abstract] [Full Text] [Related]

  • 19. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A, Hannesdottir K, Jaeger J, Annas P, Segerdahl M, Karlsson P, Sjögren N, von Rosen T, Miller F.
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [Abstract] [Full Text] [Related]

  • 20. Verbal repetition in patients with Alzheimer's disease who receive donepezil.
    Asp E, Cloutier F, Fay S, Cook C, Robertson ML, Fisk J, Dei DW, Rockwood K.
    Int J Geriatr Psychiatry; 2006 May; 21(5):426-31. PubMed ID: 16676290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.